Levothyroxine liquid formulations
The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
1. A liquid formulation comprising
levothyroxine or a pharmaceutically acceptable salt thereof;
a stabilizing agent comprising tromethamine;
not more than 2% liothyronine (T3); and
water;
wherein the formulation retains at least about 95% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for 12 months at 25±2° C., and retains at least about 95% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for 2 months at 40±2° C.
2. The formulation of claim 1 , wherein levothyroxine or a pharmaceutically acceptable salt thereof is levothyroxine sodium.
3. The formulation of claim 2 , wherein levothyroxine sodium is present at a concentration of from about 5 mcg/mL to about 500 mcg/mL.
4. The formulation of claim 1 , wherein the tromethamine is present at a concentration of about 1 mg/mL to about 50 mg/mL.
5. The formulation of claim 1 , wherein the stabilizing agent comprises a salt of iodine.
6. The formulation of claim 5 , wherein the salt of iodine is sodium iodide or potassium iodide.
7. The formulation of claim 6 , wherein the salt of iodine is sodium iodide which is present at a concentration of about 10 mcg/mL to about 500 mcg/mL.
8. The formulation of claim 1 , wherein the formulation has a pH of from about 9.0 to about 11.5.
9. The formulation of claim 8 , wherein the formulation has a pH of from about 9.8 to about 10.8.
10. The formulation of claim 1 , wherein the formulation contains not more than 1.5% liothyronine (T3).
11. The formulation of claim 1 , wherein the formulation contains not more than 1.0% liothyronine (T3).
12. The formulation of claim 1 , wherein the formulation contains not more than 5.0% total impurities.
13. The formulation of claim 1 , wherein the formulation contains not more than 2.5% total impurities.
14. The formulation of claim 1 , wherein the formulation retains at least about 90% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for at least 18 months at 25±2° C.
15. The formulation of claim 1 , wherein the formulation retains at least about 90% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for at least 24 months at 25±2° C.
16. The formulation of claim 1 , wherein the formulation does not contain a buffer.
17. The formulation of claim 1 , wherein the formulation is a ready-to-use formulation contained within a vial, ampoule, cartridge, syringe, or bag.